Immuno Oncology

• OPDIVO® (nivolumab) + chemotherapy (fluoropyrimidine + platinum-based) for the first-line (1L) treatment of metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, regardless of PD-L1 status

• FDA Approves Neoadjuvant OPDIVO® and Chemotherapy Combination for Early Stage Non Small Cell Lung Cancer

• FDA Approves YESCARTA® for Second Line Treatment of Large B-cell Lymphoma

• FDA Approves Single Agent KEYTRUDA® for Advanced Endometrial Carcinoma

• FDA Approves LAG-3 Inhibitor OPDUALAG® and OPVIDO® in Advanced Untreated Melanoma

• Association of Gut Microbiome with Immune Checkpoint Inhibitor Response in Advanced Melanoma

• Platelet-to-Lymphocyte Ratio Predicts the Efficacy of KEYTRUDA® in Patients with Urothelial Carcinoma

• OPDIVO® Combination Improves Overall Survival in Advanced Esophageal Carcinoma

• LAG-3 Inhibitor Relatlimab and OPVIDO® in Advanced Untreated Melanoma

• KRAS Variant Status and Outcomes with Immune Checkpoint Inhibitor-Based Therapy in Advanced Non Small Cell Lung Cancer

• Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma

• FDA Approves TECENTRIQ® as Adjuvant Treatment for Non Small Cell Lung Cancer

• Durable Survival Benefit with First Line OPDIVO® plus YERVOY® and a Limited Course of Chemotherapy

• KEYTRUDA® in Combination with Chemotherapy Improves Overall Survival in Triple Negative Breast Cancer

• KRAS Variant Status and Outcomes with Immune Checkpoint Inhibitor-Based Therapy in Advanced Non Small Cell Lung Cancer

• FDA Approves KEYTRUDA® for High Risk Early Stage Triple Negative Breast Cancer

• Long Term Survival Benefit in Advanced Melanoma with OPDIVO® plus YERVOY®

• Adjuvant TECENTRIQ® Improves Disease Free Survival in Early Stage Non Small Cell Lung Cancer

• FDA Approves KEYTRUDA® plus Trastuzumab and Chemotherapy for HER2 Positive Gastric or Gastroesophageal Junction Cancer

• Late Breaking Abstract – ASCO 2021: Adjuvant KEYTRUDA® Improves Disease Free Survival in Renal Cell Carcinoma